Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after Lu-177-octreotate

Kimberly Kamp, B Gumz, R.A. Feelders, Dik Kwekkeboom, G Kaltsas, FP Costa, W.W. de Herder

Research output: Contribution to journalArticleAcademicpeer-review

30 Citations (Scopus)

Abstract

Although Lu-177-octreotate is an effective treatment for patients with gastroentero-pancreatic neuroendocrine tumors (GEP-NETs), some patients will fail or develop disease progression necessitating further treatment. We examined whether the safety and efficacy of everolimus after prior treatment with Lu-177-octreotate is different from the published safety profile of everolimus in GEP-NETs. In this multicenter study, 24 GEP-NET patients were included. Adverse events were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Tumor response was measured according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.0. Major clinical adverse events (grade 3 or 4) during treatment with everolimus were hyperglycemia (20.8%), fatigue (8.3%), thrombocytopenia (8.3%), and elevated alanine transaminase levels (8.3%). By radiological review, there were four partial responses (16.7%), five patients (62.5%) with stable disease, and three patients (12.5%) with progressive disease. For two patients (8.3%), no data on tumor response were available. Median progression-free survival (PFS) was 13.1 months (95% CI, 11.5-21.2). Median PFS of the current study was longer when compared with the RADIANT-3 trial (13.1 vs 11.4 months) and shorter when compared with the RADIANT-1 trial (13.1 vs 16.7 months). In conclusion, the safety profile of everolimus is not influenced by previous treatment with peptide receptor radiotherapy.
Original languageUndefined/Unknown
Pages (from-to)825-831
Number of pages7
JournalEndocrine-Related Cancer
Volume20
Issue number6
DOIs
Publication statusPublished - 2013

Cite this